Literature DB >> 18568687

Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.

Sverre E Kjeldsen1, Kenneth A Jamerson, George L Bakris, Bertram Pitt, Björn Dahlöf, Eric J Velazquez, Jitendra Gupte, Linda Staikos, Tsushung A Hua, Victor Shi, Allen Hester, Jaakko Tuomilehto, Jan Ostergren, Hans Ibsen, Michael Weber.   

Abstract

BACKGROUND: Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) is an outcome study investigating aggressive antihypertensive combination treatment. It has achieved a larger fraction of overall patients with blood pressure (BP) <140/90 mmHg (73.3%) and diabetic patients <130/80 mmHg (43.3%) at 12 months of follow-up than any other large outcomes trial. We have analyzed baseline predictors of BPs and BP control at 12 months.
METHODS: Blinded baseline and 12-month BP was available in 10,173 patients of whom 6132 had diabetes. Univariate and multivariate logistic regression models were used for BP control at 12 months; simple and multiple regression models were used for absolute BP value at 12 months. A stepwise procedure was used to select significant predictors in multivariate analyses.
RESULTS: Mean (SD) BP fell from 145.5/80.2 mmHg (18.2/10.7 mmHg) at randomization to 132.7/74.7 mmHg (16/9.6 mmHg) at 12 months. The main baseline predictors of achieving BP control were region (USA), Caucasian race and taking lipid-lowering drugs. The predictors of uncontrolled BP were higher baseline systolic BP values, more previous antihypertensive medications, proteinuria and previous thiazide use.
CONCLUSION: Patients in the USA, Caucasians and patients taking lipid-lowering therapy were most likely to reach BP targets with combination therapy. Strong predictors of uncontrolled hypertension were more severe hypertension, an established need for more antihypertensive drugs and target organ damage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568687     DOI: 10.1080/08037050801972857

Source DB:  PubMed          Journal:  Blood Press        ISSN: 0803-7051            Impact factor:   2.835


  11 in total

1.  Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide.

Authors:  Peter Bramlage; Reinhard Ketelhut; Eva-Maria Fronk; Wolf-Peter Wolf; Rüdiger Smolnik; Claudia Zemmrich; Roland E Schmieder
Journal:  Clin Drug Investig       Date:  2014-06       Impact factor: 2.859

2.  [Hypertension short message service].

Authors:  Dieter Magometschnigg; Gustav Rothmayer
Journal:  Wien Med Wochenschr       Date:  2011-07

3.  Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.

Authors:  S G Chrysant; J Lee; M Melino; S Karki; R Heyrman
Journal:  J Hum Hypertens       Date:  2010-02-18       Impact factor: 3.012

4.  Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network.

Authors:  Brent M Egan; Yumin Zhao; Jiexiang Li; W Adam Brzezinski; Thomas M Todoran; Robert D Brook; David A Calhoun
Journal:  Hypertension       Date:  2013-08-05       Impact factor: 10.190

5.  Effectiveness of a patient-centered medical home model of primary care versus standard care on blood pressure outcomes among hypertensive patients.

Authors:  James Rufus John; W Kathy Tannous; Amanda Jones
Journal:  Hypertens Res       Date:  2020-04-01       Impact factor: 3.872

6.  Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial.

Authors:  Simon Stewart; Melinda J Carrington; Carla H Swemmer; Craig Anderson; Nicol P Kurstjens; John Amerena; Alex Brown; Louise M Burrell; Ferdinandus J de Looze; Mark Harris; Joseph Hung; Henry Krum; Mark Nelson; Markus Schlaich; Nigel P Stocks; Garry L Jennings
Journal:  BMJ       Date:  2012-11-20

7.  Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysis.

Authors:  Torbjørn Wisløff; Randi M Selmer; Sigrun Halvorsen; Atle Fretheim; Ole F Norheim; Ivar Sønbø Kristiansen
Journal:  BMC Cardiovasc Disord       Date:  2012-04-04       Impact factor: 2.298

8.  Results of treatment with telmisartan-amlodipine in hypertensive patients.

Authors:  Thomas W Littlejohn; Claudio R Majul; Rafael Olvera; Mary Seeber; Maureen Kobe; Robert Guthrie; Wille Oigman
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-04       Impact factor: 3.738

9.  Economic impact of switching to fixed-dose combination therapy for Japanese hypertensive patients: a retrospective cost analysis.

Authors:  Manabu Akazawa; Katsushi Fukuoka
Journal:  BMC Health Serv Res       Date:  2013-04-03       Impact factor: 2.655

10.  Development of an HPLC-UV Method for the Analysis of Drugs Used for Combined Hypertension Therapy in Pharmaceutical Preparations and Human Plasma.

Authors:  Serife Evrim Kepekci Tekkeli
Journal:  J Anal Methods Chem       Date:  2013-03-24       Impact factor: 2.193

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.